Virus Surveillance in Pediatric Solid Organ Transplant Recipients
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 4/2/2016 |
| Start Date: | June 2001 |
| End Date: | March 2012 |
| Contact: | Jodi Smith, MD, MPH |
| Email: | jodi.smith@seattlechildrens.org |
| Phone: | 206-987-2524 |
Virus Surveillance in Pediatric Solid Organ Transplant Recipients: Identifying Risk Factors for PTLD and Other Complications Post-Transplant
Viral infections are an important complication of transplantation. Immunosuppressive therapy
interferes with T cell immunity resulting in a high incidence of viral infection. Newer
agents, such as mycophenolate mofetil (MMF) and sirolimus, have been associated with an
increased risk of herpes virus infection. The introduction of these more potent
immunosuppressive agents over the past decade correlates with an increase in the rate of
hospitalizations of transplant patients with infections. This prospective study will
determine the role of sub-clinical herpes virus infections in the development of
complications such as chronic allograft nephropathy (CAN) and Post Transplant
Lymphoproliferative Disease (PTLD). By focusing on treatable herpes virus infections, these
studies have the potential to identify therapeutic strategies that can be used to diminish
the burden of graft loss from CAN, significantly improving renal allograft survival and
quality of life in transplant patients. Future specific interventions to test the hypothesis
of a direct causal relationship between sub-clinical herpes virus infection and CAN may
include the use of anti-viral therapy in response to sub-clinical infection of the renal
allograft and/or peripheral blood.
interferes with T cell immunity resulting in a high incidence of viral infection. Newer
agents, such as mycophenolate mofetil (MMF) and sirolimus, have been associated with an
increased risk of herpes virus infection. The introduction of these more potent
immunosuppressive agents over the past decade correlates with an increase in the rate of
hospitalizations of transplant patients with infections. This prospective study will
determine the role of sub-clinical herpes virus infections in the development of
complications such as chronic allograft nephropathy (CAN) and Post Transplant
Lymphoproliferative Disease (PTLD). By focusing on treatable herpes virus infections, these
studies have the potential to identify therapeutic strategies that can be used to diminish
the burden of graft loss from CAN, significantly improving renal allograft survival and
quality of life in transplant patients. Future specific interventions to test the hypothesis
of a direct causal relationship between sub-clinical herpes virus infection and CAN may
include the use of anti-viral therapy in response to sub-clinical infection of the renal
allograft and/or peripheral blood.
Inclusion Criteria:
- Age from birth to 21 years
- All solid organ transplant recipients receiving their care at Seattle Children's
Hospital
- Signed consent, and when age appropriate, signed assent
Exclusion Criteria:
- Lack of consent
We found this trial at
1
site
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
Click here to add this to my saved trials
